nodes	percent_of_prediction	percent_of_DWPC	metapath
Fosinopril—ACE—prostate cancer	0.594	1	CbGaD
Fosinopril—ACE—urine—prostate cancer	0.0086	0.208	CbGeAlD
Fosinopril—SLC15A1—epithelium—prostate cancer	0.00316	0.0764	CbGeAlD
Fosinopril—ACE—prostate gland—prostate cancer	0.00309	0.0745	CbGeAlD
Fosinopril—SLC15A1—renal system—prostate cancer	0.00294	0.0709	CbGeAlD
Fosinopril—SLC15A2—prostate gland—prostate cancer	0.00269	0.065	CbGeAlD
Fosinopril—ACE—seminal vesicle—prostate cancer	0.00261	0.063	CbGeAlD
Fosinopril—SLC15A2—seminal vesicle—prostate cancer	0.00228	0.055	CbGeAlD
Fosinopril—ACE—epithelium—prostate cancer	0.00227	0.0548	CbGeAlD
Fosinopril—ACE—renal system—prostate cancer	0.0021	0.0508	CbGeAlD
Fosinopril—ACE—urethra—prostate cancer	0.00207	0.0499	CbGeAlD
Fosinopril—SLC15A2—renal system—prostate cancer	0.00183	0.0443	CbGeAlD
Fosinopril—SLC15A2—urethra—prostate cancer	0.0018	0.0435	CbGeAlD
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—MME—prostate cancer	0.0017	0.0891	CbGpPWpGaD
Fosinopril—ACE—bone marrow—prostate cancer	0.00159	0.0384	CbGeAlD
Fosinopril—ACE—testis—prostate cancer	0.00136	0.0328	CbGeAlD
Fosinopril—ACE—Metabolism of Angiotensinogen to Angiotensins—CTSD—prostate cancer	0.00123	0.0647	CbGpPWpGaD
Fosinopril—SLC15A2—testis—prostate cancer	0.00119	0.0286	CbGeAlD
Fosinopril—ACE—lymph node—prostate cancer	0.000986	0.0238	CbGeAlD
Fosinopril—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.000943	0.0495	CbGpPWpGaD
Fosinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC7A1—prostate cancer	0.000875	0.0459	CbGpPWpGaD
Fosinopril—Spirapril—ACE—prostate cancer	0.000862	0.183	CrCbGaD
Fosinopril—SLC15A2—lymph node—prostate cancer	0.00086	0.0208	CbGeAlD
Fosinopril—Lisinopril—ACE—prostate cancer	0.000769	0.163	CrCbGaD
Fosinopril—Cilazapril—ACE—prostate cancer	0.000769	0.163	CrCbGaD
Fosinopril—Trandolapril—ACE—prostate cancer	0.000744	0.158	CrCbGaD
Fosinopril—Ramipril—ACE—prostate cancer	0.000744	0.158	CrCbGaD
Fosinopril—Enalapril—ACE—prostate cancer	0.000564	0.12	CrCbGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000555	0.0291	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC7A1—prostate cancer	0.000515	0.027	CbGpPWpGaD
Fosinopril—ACE—ACE Inhibitor Pathway—NOS3—prostate cancer	0.000487	0.0255	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—MME—prostate cancer	0.000446	0.0234	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—GRP—prostate cancer	0.000428	0.0224	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000349	0.0183	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000349	0.0183	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—ACHE—prostate cancer	0.000342	0.018	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—CTSD—prostate cancer	0.000324	0.017	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC26A4—prostate cancer	0.000324	0.017	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC12A2—prostate cancer	0.000324	0.017	CbGpPWpGaD
Fosinopril—ACE—ACE Inhibitor Pathway—TGFB1—prostate cancer	0.000322	0.0169	CbGpPWpGaD
Fosinopril—SLC15A2—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000286	0.015	CbGpPWpGaD
Fosinopril—SLC15A1—Amino acid and oligopeptide SLC transporters—SLC5A5—prostate cancer	0.000265	0.0139	CbGpPWpGaD
Fosinopril—Enalapril—CYP3A4—prostate cancer	0.000265	0.0562	CrCbGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.000248	0.013	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC7A1—prostate cancer	0.00023	0.0121	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—IGFBP6—prostate cancer	0.000225	0.0118	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—TUSC3—prostate cancer	0.000225	0.0118	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—GALNT3—prostate cancer	0.000201	0.0105	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—SSR2—prostate cancer	0.000201	0.0105	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000196	0.0103	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—SPON2—prostate cancer	0.000184	0.00963	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—HERPUD1—prostate cancer	0.000184	0.00963	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC39A1—prostate cancer	0.000182	0.00955	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—LEP—prostate cancer	0.000179	0.00941	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—KLK3—prostate cancer	0.000171	0.00895	CbGpPWpGaD
Fosinopril—SLC15A2—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000168	0.00882	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—KLK2—prostate cancer	0.00016	0.00842	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—RPN2—prostate cancer	0.00016	0.00842	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—MBTPS1—prostate cancer	0.00016	0.00842	CbGpPWpGaD
Fosinopril—SLC15A1—Transport of inorganic cations/anions and amino acids/oligopeptides—SLC5A5—prostate cancer	0.000156	0.00819	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000156	0.00817	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000156	0.00817	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—INS—prostate cancer	0.000153	0.00804	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—TCP1—prostate cancer	0.000152	0.00798	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—IGF1—prostate cancer	0.000148	0.00778	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—DNAJC3—prostate cancer	0.000145	0.00761	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC12A2—prostate cancer	0.000145	0.00758	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC26A4—prostate cancer	0.000145	0.00758	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—GCNT1—prostate cancer	0.000139	0.0073	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—PDIA3—prostate cancer	0.000134	0.00702	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—EIF3H—prostate cancer	0.000129	0.00678	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—B4GALT4—prostate cancer	0.000129	0.00678	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—TPP1—prostate cancer	0.000129	0.00678	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000126	0.00663	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000126	0.00661	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—F9—prostate cancer	0.000125	0.00657	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—MUC4—prostate cancer	0.000118	0.00621	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A3—prostate cancer	0.000117	0.00615	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC7A1—prostate cancer	0.000117	0.00614	CbGpPWpGaD
Fosinopril—ACE—Peptide hormone metabolism—CTNNB1—prostate cancer	0.00011	0.00577	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—RPL12—prostate cancer	0.000103	0.00542	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	0.000103	0.0054	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC39A1—prostate cancer	9.97e-05	0.00523	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—HSP90B1—prostate cancer	9.8e-05	0.00514	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC22A1—prostate cancer	9.56e-05	0.00502	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—EIF3A—prostate cancer	9.49e-05	0.00498	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC39A1—prostate cancer	9.25e-05	0.00485	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—MME—prostate cancer	8.43e-05	0.00442	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CYP7B1—prostate cancer	8.12e-05	0.00426	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—GRP—prostate cancer	8.07e-05	0.00423	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC12A2—prostate cancer	7.92e-05	0.00415	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC26A4—prostate cancer	7.92e-05	0.00415	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—RPL10—prostate cancer	7.84e-05	0.00411	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CYP7B1—prostate cancer	7.54e-05	0.00396	CbGpPWpGaD
Fosinopril—SLC15A2—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	7.52e-05	0.00394	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC26A4—prostate cancer	7.35e-05	0.00385	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC12A2—prostate cancer	7.35e-05	0.00385	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—ATF3—prostate cancer	7.03e-05	0.00369	CbGpPWpGaD
Fosinopril—SLC15A1—SLC-mediated transmembrane transport—SLC5A5—prostate cancer	6.97e-05	0.00366	CbGpPWpGaD
Fosinopril—Abdominal pain—Etoposide—prostate cancer	6.78e-05	0.000199	CcSEcCtD
Fosinopril—Body temperature increased—Etoposide—prostate cancer	6.78e-05	0.000199	CcSEcCtD
Fosinopril—Vertigo—Prednisone—prostate cancer	6.76e-05	0.000199	CcSEcCtD
Fosinopril—Haemorrhage—Epirubicin—prostate cancer	6.76e-05	0.000199	CcSEcCtD
Fosinopril—Hepatitis—Epirubicin—prostate cancer	6.76e-05	0.000199	CcSEcCtD
Fosinopril—Thrombocytopenia—Capecitabine—prostate cancer	6.75e-05	0.000198	CcSEcCtD
Fosinopril—Syncope—Prednisone—prostate cancer	6.75e-05	0.000198	CcSEcCtD
Fosinopril—Tachycardia—Capecitabine—prostate cancer	6.73e-05	0.000198	CcSEcCtD
Fosinopril—Hypoaesthesia—Epirubicin—prostate cancer	6.73e-05	0.000198	CcSEcCtD
Fosinopril—Pharyngitis—Epirubicin—prostate cancer	6.71e-05	0.000197	CcSEcCtD
Fosinopril—Hyperhidrosis—Capecitabine—prostate cancer	6.67e-05	0.000196	CcSEcCtD
Fosinopril—Oedema peripheral—Epirubicin—prostate cancer	6.66e-05	0.000196	CcSEcCtD
Fosinopril—Hypotension—Docetaxel—prostate cancer	6.66e-05	0.000195	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—IGFBP3—prostate cancer	6.62e-05	0.00347	CbGpPWpGaD
Fosinopril—Loss of consciousness—Prednisone—prostate cancer	6.62e-05	0.000194	CcSEcCtD
Fosinopril—Epistaxis—Doxorubicin—prostate cancer	6.58e-05	0.000193	CcSEcCtD
Fosinopril—Anorexia—Capecitabine—prostate cancer	6.58e-05	0.000193	CcSEcCtD
Fosinopril—Nausea—Estradiol—prostate cancer	6.57e-05	0.000193	CcSEcCtD
Fosinopril—Vomiting—Mitoxantrone—prostate cancer	6.55e-05	0.000192	CcSEcCtD
Fosinopril—Sinusitis—Doxorubicin—prostate cancer	6.54e-05	0.000192	CcSEcCtD
Fosinopril—Visual impairment—Epirubicin—prostate cancer	6.52e-05	0.000191	CcSEcCtD
Fosinopril—Agranulocytosis—Doxorubicin—prostate cancer	6.51e-05	0.000191	CcSEcCtD
Fosinopril—Hypertension—Prednisone—prostate cancer	6.5e-05	0.000191	CcSEcCtD
Fosinopril—Rash—Mitoxantrone—prostate cancer	6.5e-05	0.000191	CcSEcCtD
Fosinopril—Dermatitis—Mitoxantrone—prostate cancer	6.49e-05	0.000191	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Docetaxel—prostate cancer	6.49e-05	0.000191	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—ACHE—prostate cancer	6.46e-05	0.00339	CbGpPWpGaD
Fosinopril—Headache—Mitoxantrone—prostate cancer	6.46e-05	0.00019	CcSEcCtD
Fosinopril—Hypotension—Capecitabine—prostate cancer	6.45e-05	0.000189	CcSEcCtD
Fosinopril—Insomnia—Docetaxel—prostate cancer	6.44e-05	0.000189	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC22A3—prostate cancer	6.42e-05	0.00337	CbGpPWpGaD
Fosinopril—Myalgia—Prednisone—prostate cancer	6.41e-05	0.000188	CcSEcCtD
Fosinopril—Arthralgia—Prednisone—prostate cancer	6.41e-05	0.000188	CcSEcCtD
Fosinopril—Paraesthesia—Docetaxel—prostate cancer	6.4e-05	0.000188	CcSEcCtD
Fosinopril—Erythema multiforme—Epirubicin—prostate cancer	6.4e-05	0.000188	CcSEcCtD
Fosinopril—Bradycardia—Doxorubicin—prostate cancer	6.37e-05	0.000187	CcSEcCtD
Fosinopril—Dyspnoea—Docetaxel—prostate cancer	6.35e-05	0.000186	CcSEcCtD
Fosinopril—Somnolence—Docetaxel—prostate cancer	6.33e-05	0.000186	CcSEcCtD
Fosinopril—Discomfort—Prednisone—prostate cancer	6.33e-05	0.000186	CcSEcCtD
Fosinopril—Hypersensitivity—Etoposide—prostate cancer	6.32e-05	0.000185	CcSEcCtD
Fosinopril—Tinnitus—Epirubicin—prostate cancer	6.31e-05	0.000185	CcSEcCtD
Fosinopril—Haemoglobin—Doxorubicin—prostate cancer	6.29e-05	0.000185	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Capecitabine—prostate cancer	6.28e-05	0.000184	CcSEcCtD
Fosinopril—Flushing—Epirubicin—prostate cancer	6.28e-05	0.000184	CcSEcCtD
Fosinopril—Rhinitis—Doxorubicin—prostate cancer	6.27e-05	0.000184	CcSEcCtD
Fosinopril—Dyspepsia—Docetaxel—prostate cancer	6.27e-05	0.000184	CcSEcCtD
Fosinopril—Haemorrhage—Doxorubicin—prostate cancer	6.26e-05	0.000184	CcSEcCtD
Fosinopril—Hepatitis—Doxorubicin—prostate cancer	6.26e-05	0.000184	CcSEcCtD
Fosinopril—Insomnia—Capecitabine—prostate cancer	6.24e-05	0.000183	CcSEcCtD
Fosinopril—Hypoaesthesia—Doxorubicin—prostate cancer	6.23e-05	0.000183	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—RPS19—prostate cancer	6.21e-05	0.00326	CbGpPWpGaD
Fosinopril—Pharyngitis—Doxorubicin—prostate cancer	6.21e-05	0.000182	CcSEcCtD
Fosinopril—Paraesthesia—Capecitabine—prostate cancer	6.19e-05	0.000182	CcSEcCtD
Fosinopril—Decreased appetite—Docetaxel—prostate cancer	6.19e-05	0.000182	CcSEcCtD
Fosinopril—Oedema peripheral—Doxorubicin—prostate cancer	6.17e-05	0.000181	CcSEcCtD
Fosinopril—Asthenia—Etoposide—prostate cancer	6.15e-05	0.000181	CcSEcCtD
Fosinopril—Dyspnoea—Capecitabine—prostate cancer	6.15e-05	0.000181	CcSEcCtD
Fosinopril—Oedema—Prednisone—prostate cancer	6.14e-05	0.00018	CcSEcCtD
Fosinopril—Anaphylactic shock—Prednisone—prostate cancer	6.14e-05	0.00018	CcSEcCtD
Fosinopril—Fatigue—Docetaxel—prostate cancer	6.14e-05	0.00018	CcSEcCtD
Fosinopril—Nausea—Mitoxantrone—prostate cancer	6.12e-05	0.00018	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—CTSD—prostate cancer	6.12e-05	0.00321	CbGpPWpGaD
Fosinopril—Infection—Prednisone—prostate cancer	6.1e-05	0.000179	CcSEcCtD
Fosinopril—Constipation—Docetaxel—prostate cancer	6.09e-05	0.000179	CcSEcCtD
Fosinopril—Pain—Docetaxel—prostate cancer	6.09e-05	0.000179	CcSEcCtD
Fosinopril—Dyspepsia—Capecitabine—prostate cancer	6.07e-05	0.000178	CcSEcCtD
Fosinopril—Chills—Epirubicin—prostate cancer	6.07e-05	0.000178	CcSEcCtD
Fosinopril—Pruritus—Etoposide—prostate cancer	6.07e-05	0.000178	CcSEcCtD
Fosinopril—Shock—Prednisone—prostate cancer	6.05e-05	0.000177	CcSEcCtD
Fosinopril—Arrhythmia—Epirubicin—prostate cancer	6.04e-05	0.000177	CcSEcCtD
Fosinopril—Visual impairment—Doxorubicin—prostate cancer	6.03e-05	0.000177	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—THBS1—prostate cancer	6.03e-05	0.00316	CbGpPWpGaD
Fosinopril—Tachycardia—Prednisone—prostate cancer	6e-05	0.000176	CcSEcCtD
Fosinopril—Decreased appetite—Capecitabine—prostate cancer	6e-05	0.000176	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A3—prostate cancer	5.96e-05	0.00313	CbGpPWpGaD
Fosinopril—Fatigue—Capecitabine—prostate cancer	5.95e-05	0.000175	CcSEcCtD
Fosinopril—Hyperhidrosis—Prednisone—prostate cancer	5.94e-05	0.000174	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.93e-05	0.00311	CbGpPWpGaD
Fosinopril—Erythema multiforme—Doxorubicin—prostate cancer	5.92e-05	0.000174	CcSEcCtD
Fosinopril—Constipation—Capecitabine—prostate cancer	5.9e-05	0.000173	CcSEcCtD
Fosinopril—Pain—Capecitabine—prostate cancer	5.9e-05	0.000173	CcSEcCtD
Fosinopril—Feeling abnormal—Docetaxel—prostate cancer	5.87e-05	0.000172	CcSEcCtD
Fosinopril—Diarrhoea—Etoposide—prostate cancer	5.87e-05	0.000172	CcSEcCtD
Fosinopril—Anorexia—Prednisone—prostate cancer	5.86e-05	0.000172	CcSEcCtD
Fosinopril—Tinnitus—Doxorubicin—prostate cancer	5.84e-05	0.000171	CcSEcCtD
Fosinopril—Gastrointestinal pain—Docetaxel—prostate cancer	5.83e-05	0.000171	CcSEcCtD
Fosinopril—Flushing—Doxorubicin—prostate cancer	5.81e-05	0.000171	CcSEcCtD
Fosinopril—Flatulence—Epirubicin—prostate cancer	5.8e-05	0.00017	CcSEcCtD
Fosinopril—Tension—Epirubicin—prostate cancer	5.78e-05	0.00017	CcSEcCtD
Fosinopril—Dysgeusia—Epirubicin—prostate cancer	5.77e-05	0.000169	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—CALR—prostate cancer	5.73e-05	0.003	CbGpPWpGaD
Fosinopril—Nervousness—Epirubicin—prostate cancer	5.72e-05	0.000168	CcSEcCtD
Fosinopril—Feeling abnormal—Capecitabine—prostate cancer	5.68e-05	0.000167	CcSEcCtD
Fosinopril—Dizziness—Etoposide—prostate cancer	5.67e-05	0.000166	CcSEcCtD
Fosinopril—Muscle spasms—Epirubicin—prostate cancer	5.66e-05	0.000166	CcSEcCtD
Fosinopril—Gastrointestinal pain—Capecitabine—prostate cancer	5.64e-05	0.000166	CcSEcCtD
Fosinopril—Abdominal pain—Docetaxel—prostate cancer	5.63e-05	0.000165	CcSEcCtD
Fosinopril—Body temperature increased—Docetaxel—prostate cancer	5.63e-05	0.000165	CcSEcCtD
Fosinopril—Chills—Doxorubicin—prostate cancer	5.62e-05	0.000165	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Prednisone—prostate cancer	5.6e-05	0.000164	CcSEcCtD
Fosinopril—Arrhythmia—Doxorubicin—prostate cancer	5.59e-05	0.000164	CcSEcCtD
Fosinopril—Insomnia—Prednisone—prostate cancer	5.56e-05	0.000163	CcSEcCtD
Fosinopril—Vision blurred—Epirubicin—prostate cancer	5.55e-05	0.000163	CcSEcCtD
Fosinopril—Paraesthesia—Prednisone—prostate cancer	5.52e-05	0.000162	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—ABCG5—prostate cancer	5.5e-05	0.00289	CbGpPWpGaD
Fosinopril—Urticaria—Capecitabine—prostate cancer	5.48e-05	0.000161	CcSEcCtD
Fosinopril—Ill-defined disorder—Epirubicin—prostate cancer	5.46e-05	0.00016	CcSEcCtD
Fosinopril—Abdominal pain—Capecitabine—prostate cancer	5.45e-05	0.00016	CcSEcCtD
Fosinopril—Body temperature increased—Capecitabine—prostate cancer	5.45e-05	0.00016	CcSEcCtD
Fosinopril—Vomiting—Etoposide—prostate cancer	5.45e-05	0.00016	CcSEcCtD
Fosinopril—Anaemia—Epirubicin—prostate cancer	5.44e-05	0.00016	CcSEcCtD
Fosinopril—Agitation—Epirubicin—prostate cancer	5.41e-05	0.000159	CcSEcCtD
Fosinopril—Dyspepsia—Prednisone—prostate cancer	5.41e-05	0.000159	CcSEcCtD
Fosinopril—Rash—Etoposide—prostate cancer	5.41e-05	0.000159	CcSEcCtD
Fosinopril—Dermatitis—Etoposide—prostate cancer	5.4e-05	0.000159	CcSEcCtD
Fosinopril—Headache—Etoposide—prostate cancer	5.37e-05	0.000158	CcSEcCtD
Fosinopril—Flatulence—Doxorubicin—prostate cancer	5.37e-05	0.000158	CcSEcCtD
Fosinopril—Tension—Doxorubicin—prostate cancer	5.35e-05	0.000157	CcSEcCtD
Fosinopril—Decreased appetite—Prednisone—prostate cancer	5.34e-05	0.000157	CcSEcCtD
Fosinopril—Dysgeusia—Doxorubicin—prostate cancer	5.34e-05	0.000157	CcSEcCtD
Fosinopril—Malaise—Epirubicin—prostate cancer	5.31e-05	0.000156	CcSEcCtD
Fosinopril—Fatigue—Prednisone—prostate cancer	5.3e-05	0.000156	CcSEcCtD
Fosinopril—Nervousness—Doxorubicin—prostate cancer	5.29e-05	0.000155	CcSEcCtD
Fosinopril—Vertigo—Epirubicin—prostate cancer	5.29e-05	0.000155	CcSEcCtD
Fosinopril—Syncope—Epirubicin—prostate cancer	5.28e-05	0.000155	CcSEcCtD
Fosinopril—Leukopenia—Epirubicin—prostate cancer	5.27e-05	0.000155	CcSEcCtD
Fosinopril—Constipation—Prednisone—prostate cancer	5.25e-05	0.000154	CcSEcCtD
Fosinopril—Hypersensitivity—Docetaxel—prostate cancer	5.25e-05	0.000154	CcSEcCtD
Fosinopril—Muscle spasms—Doxorubicin—prostate cancer	5.24e-05	0.000154	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC22A1—prostate cancer	5.23e-05	0.00275	CbGpPWpGaD
Fosinopril—Palpitations—Epirubicin—prostate cancer	5.2e-05	0.000153	CcSEcCtD
Fosinopril—Loss of consciousness—Epirubicin—prostate cancer	5.18e-05	0.000152	CcSEcCtD
Fosinopril—Cough—Epirubicin—prostate cancer	5.14e-05	0.000151	CcSEcCtD
Fosinopril—Vision blurred—Doxorubicin—prostate cancer	5.13e-05	0.000151	CcSEcCtD
Fosinopril—Asthenia—Docetaxel—prostate cancer	5.11e-05	0.00015	CcSEcCtD
Fosinopril—Nausea—Etoposide—prostate cancer	5.09e-05	0.000149	CcSEcCtD
Fosinopril—Hypertension—Epirubicin—prostate cancer	5.08e-05	0.000149	CcSEcCtD
Fosinopril—Hypersensitivity—Capecitabine—prostate cancer	5.08e-05	0.000149	CcSEcCtD
Fosinopril—Feeling abnormal—Prednisone—prostate cancer	5.06e-05	0.000149	CcSEcCtD
Fosinopril—Ill-defined disorder—Doxorubicin—prostate cancer	5.06e-05	0.000148	CcSEcCtD
Fosinopril—Pruritus—Docetaxel—prostate cancer	5.04e-05	0.000148	CcSEcCtD
Fosinopril—Anaemia—Doxorubicin—prostate cancer	5.04e-05	0.000148	CcSEcCtD
Fosinopril—Gastrointestinal pain—Prednisone—prostate cancer	5.02e-05	0.000147	CcSEcCtD
Fosinopril—Chest pain—Epirubicin—prostate cancer	5.01e-05	0.000147	CcSEcCtD
Fosinopril—Myalgia—Epirubicin—prostate cancer	5.01e-05	0.000147	CcSEcCtD
Fosinopril—Arthralgia—Epirubicin—prostate cancer	5.01e-05	0.000147	CcSEcCtD
Fosinopril—Agitation—Doxorubicin—prostate cancer	5.01e-05	0.000147	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—GNG5—prostate cancer	4.98e-05	0.00261	CbGpPWpGaD
Fosinopril—Discomfort—Epirubicin—prostate cancer	4.95e-05	0.000145	CcSEcCtD
Fosinopril—Asthenia—Capecitabine—prostate cancer	4.95e-05	0.000145	CcSEcCtD
Fosinopril—Malaise—Doxorubicin—prostate cancer	4.91e-05	0.000144	CcSEcCtD
Fosinopril—Dry mouth—Epirubicin—prostate cancer	4.9e-05	0.000144	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—PLAUR—prostate cancer	4.9e-05	0.00257	CbGpPWpGaD
Fosinopril—Vertigo—Doxorubicin—prostate cancer	4.9e-05	0.000144	CcSEcCtD
Fosinopril—Syncope—Doxorubicin—prostate cancer	4.89e-05	0.000143	CcSEcCtD
Fosinopril—Urticaria—Prednisone—prostate cancer	4.88e-05	0.000143	CcSEcCtD
Fosinopril—Pruritus—Capecitabine—prostate cancer	4.88e-05	0.000143	CcSEcCtD
Fosinopril—Leukopenia—Doxorubicin—prostate cancer	4.88e-05	0.000143	CcSEcCtD
Fosinopril—Diarrhoea—Docetaxel—prostate cancer	4.87e-05	0.000143	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC22A1—prostate cancer	4.86e-05	0.00255	CbGpPWpGaD
Fosinopril—Abdominal pain—Prednisone—prostate cancer	4.86e-05	0.000143	CcSEcCtD
Fosinopril—Body temperature increased—Prednisone—prostate cancer	4.86e-05	0.000143	CcSEcCtD
Fosinopril—Confusional state—Epirubicin—prostate cancer	4.85e-05	0.000142	CcSEcCtD
Fosinopril—Palpitations—Doxorubicin—prostate cancer	4.81e-05	0.000141	CcSEcCtD
Fosinopril—Oedema—Epirubicin—prostate cancer	4.81e-05	0.000141	CcSEcCtD
Fosinopril—Anaphylactic shock—Epirubicin—prostate cancer	4.81e-05	0.000141	CcSEcCtD
Fosinopril—Loss of consciousness—Doxorubicin—prostate cancer	4.79e-05	0.000141	CcSEcCtD
Fosinopril—Infection—Epirubicin—prostate cancer	4.77e-05	0.00014	CcSEcCtD
Fosinopril—Cough—Doxorubicin—prostate cancer	4.75e-05	0.00014	CcSEcCtD
Fosinopril—Shock—Epirubicin—prostate cancer	4.73e-05	0.000139	CcSEcCtD
Fosinopril—Diarrhoea—Capecitabine—prostate cancer	4.72e-05	0.000139	CcSEcCtD
Fosinopril—Dizziness—Docetaxel—prostate cancer	4.71e-05	0.000138	CcSEcCtD
Fosinopril—Thrombocytopenia—Epirubicin—prostate cancer	4.71e-05	0.000138	CcSEcCtD
Fosinopril—Hypertension—Doxorubicin—prostate cancer	4.7e-05	0.000138	CcSEcCtD
Fosinopril—Tachycardia—Epirubicin—prostate cancer	4.69e-05	0.000138	CcSEcCtD
Fosinopril—Hyperhidrosis—Epirubicin—prostate cancer	4.65e-05	0.000136	CcSEcCtD
Fosinopril—Arthralgia—Doxorubicin—prostate cancer	4.64e-05	0.000136	CcSEcCtD
Fosinopril—Chest pain—Doxorubicin—prostate cancer	4.64e-05	0.000136	CcSEcCtD
Fosinopril—Myalgia—Doxorubicin—prostate cancer	4.64e-05	0.000136	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—GNG5—prostate cancer	4.62e-05	0.00242	CbGpPWpGaD
Fosinopril—Discomfort—Doxorubicin—prostate cancer	4.58e-05	0.000135	CcSEcCtD
Fosinopril—Anorexia—Epirubicin—prostate cancer	4.58e-05	0.000134	CcSEcCtD
Fosinopril—Dizziness—Capecitabine—prostate cancer	4.56e-05	0.000134	CcSEcCtD
Fosinopril—Dry mouth—Doxorubicin—prostate cancer	4.54e-05	0.000133	CcSEcCtD
Fosinopril—Vomiting—Docetaxel—prostate cancer	4.53e-05	0.000133	CcSEcCtD
Fosinopril—Hypersensitivity—Prednisone—prostate cancer	4.53e-05	0.000133	CcSEcCtD
Fosinopril—Rash—Docetaxel—prostate cancer	4.49e-05	0.000132	CcSEcCtD
Fosinopril—Hypotension—Epirubicin—prostate cancer	4.49e-05	0.000132	CcSEcCtD
Fosinopril—Dermatitis—Docetaxel—prostate cancer	4.49e-05	0.000132	CcSEcCtD
Fosinopril—Confusional state—Doxorubicin—prostate cancer	4.48e-05	0.000132	CcSEcCtD
Fosinopril—Headache—Docetaxel—prostate cancer	4.46e-05	0.000131	CcSEcCtD
Fosinopril—Oedema—Doxorubicin—prostate cancer	4.45e-05	0.000131	CcSEcCtD
Fosinopril—Anaphylactic shock—Doxorubicin—prostate cancer	4.45e-05	0.000131	CcSEcCtD
Fosinopril—Infection—Doxorubicin—prostate cancer	4.42e-05	0.00013	CcSEcCtD
Fosinopril—Asthenia—Prednisone—prostate cancer	4.41e-05	0.000129	CcSEcCtD
Fosinopril—Vomiting—Capecitabine—prostate cancer	4.39e-05	0.000129	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Epirubicin—prostate cancer	4.38e-05	0.000129	CcSEcCtD
Fosinopril—Shock—Doxorubicin—prostate cancer	4.37e-05	0.000128	CcSEcCtD
Fosinopril—Thrombocytopenia—Doxorubicin—prostate cancer	4.35e-05	0.000128	CcSEcCtD
Fosinopril—Rash—Capecitabine—prostate cancer	4.35e-05	0.000128	CcSEcCtD
Fosinopril—Pruritus—Prednisone—prostate cancer	4.35e-05	0.000128	CcSEcCtD
Fosinopril—Insomnia—Epirubicin—prostate cancer	4.35e-05	0.000128	CcSEcCtD
Fosinopril—Dermatitis—Capecitabine—prostate cancer	4.35e-05	0.000128	CcSEcCtD
Fosinopril—Tachycardia—Doxorubicin—prostate cancer	4.34e-05	0.000127	CcSEcCtD
Fosinopril—Headache—Capecitabine—prostate cancer	4.32e-05	0.000127	CcSEcCtD
Fosinopril—Paraesthesia—Epirubicin—prostate cancer	4.32e-05	0.000127	CcSEcCtD
Fosinopril—Hyperhidrosis—Doxorubicin—prostate cancer	4.3e-05	0.000126	CcSEcCtD
Fosinopril—Dyspnoea—Epirubicin—prostate cancer	4.28e-05	0.000126	CcSEcCtD
Fosinopril—Somnolence—Epirubicin—prostate cancer	4.27e-05	0.000125	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—PRKACB—prostate cancer	4.24e-05	0.00223	CbGpPWpGaD
Fosinopril—Anorexia—Doxorubicin—prostate cancer	4.24e-05	0.000124	CcSEcCtD
Fosinopril—Nausea—Docetaxel—prostate cancer	4.23e-05	0.000124	CcSEcCtD
Fosinopril—Dyspepsia—Epirubicin—prostate cancer	4.23e-05	0.000124	CcSEcCtD
Fosinopril—Diarrhoea—Prednisone—prostate cancer	4.2e-05	0.000123	CcSEcCtD
Fosinopril—Decreased appetite—Epirubicin—prostate cancer	4.18e-05	0.000123	CcSEcCtD
Fosinopril—Hypotension—Doxorubicin—prostate cancer	4.16e-05	0.000122	CcSEcCtD
Fosinopril—Fatigue—Epirubicin—prostate cancer	4.14e-05	0.000122	CcSEcCtD
Fosinopril—Pain—Epirubicin—prostate cancer	4.11e-05	0.000121	CcSEcCtD
Fosinopril—Constipation—Epirubicin—prostate cancer	4.11e-05	0.000121	CcSEcCtD
Fosinopril—Nausea—Capecitabine—prostate cancer	4.1e-05	0.00012	CcSEcCtD
Fosinopril—Dizziness—Prednisone—prostate cancer	4.06e-05	0.000119	CcSEcCtD
Fosinopril—Musculoskeletal discomfort—Doxorubicin—prostate cancer	4.05e-05	0.000119	CcSEcCtD
Fosinopril—Insomnia—Doxorubicin—prostate cancer	4.02e-05	0.000118	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—NCOA2—prostate cancer	4e-05	0.0021	CbGpPWpGaD
Fosinopril—Paraesthesia—Doxorubicin—prostate cancer	3.99e-05	0.000117	CcSEcCtD
Fosinopril—Dyspnoea—Doxorubicin—prostate cancer	3.96e-05	0.000116	CcSEcCtD
Fosinopril—Feeling abnormal—Epirubicin—prostate cancer	3.96e-05	0.000116	CcSEcCtD
Fosinopril—Somnolence—Doxorubicin—prostate cancer	3.95e-05	0.000116	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—PRKACB—prostate cancer	3.94e-05	0.00207	CbGpPWpGaD
Fosinopril—Gastrointestinal pain—Epirubicin—prostate cancer	3.93e-05	0.000115	CcSEcCtD
Fosinopril—Dyspepsia—Doxorubicin—prostate cancer	3.91e-05	0.000115	CcSEcCtD
Fosinopril—Vomiting—Prednisone—prostate cancer	3.91e-05	0.000115	CcSEcCtD
Fosinopril—Rash—Prednisone—prostate cancer	3.87e-05	0.000114	CcSEcCtD
Fosinopril—Dermatitis—Prednisone—prostate cancer	3.87e-05	0.000114	CcSEcCtD
Fosinopril—Decreased appetite—Doxorubicin—prostate cancer	3.87e-05	0.000113	CcSEcCtD
Fosinopril—Headache—Prednisone—prostate cancer	3.85e-05	0.000113	CcSEcCtD
Fosinopril—Fatigue—Doxorubicin—prostate cancer	3.83e-05	0.000113	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.82e-05	0.002	CbGpPWpGaD
Fosinopril—Urticaria—Epirubicin—prostate cancer	3.82e-05	0.000112	CcSEcCtD
Fosinopril—Constipation—Doxorubicin—prostate cancer	3.8e-05	0.000112	CcSEcCtD
Fosinopril—Pain—Doxorubicin—prostate cancer	3.8e-05	0.000112	CcSEcCtD
Fosinopril—Abdominal pain—Epirubicin—prostate cancer	3.8e-05	0.000112	CcSEcCtD
Fosinopril—Body temperature increased—Epirubicin—prostate cancer	3.8e-05	0.000112	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—NCOA2—prostate cancer	3.72e-05	0.00195	CbGpPWpGaD
Fosinopril—Feeling abnormal—Doxorubicin—prostate cancer	3.66e-05	0.000108	CcSEcCtD
Fosinopril—Nausea—Prednisone—prostate cancer	3.65e-05	0.000107	CcSEcCtD
Fosinopril—Gastrointestinal pain—Doxorubicin—prostate cancer	3.64e-05	0.000107	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—SLC5A5—prostate cancer	3.54e-05	0.00186	CbGpPWpGaD
Fosinopril—Hypersensitivity—Epirubicin—prostate cancer	3.54e-05	0.000104	CcSEcCtD
Fosinopril—Urticaria—Doxorubicin—prostate cancer	3.53e-05	0.000104	CcSEcCtD
Fosinopril—Abdominal pain—Doxorubicin—prostate cancer	3.52e-05	0.000103	CcSEcCtD
Fosinopril—Body temperature increased—Doxorubicin—prostate cancer	3.52e-05	0.000103	CcSEcCtD
Fosinopril—Asthenia—Epirubicin—prostate cancer	3.45e-05	0.000101	CcSEcCtD
Fosinopril—Pruritus—Epirubicin—prostate cancer	3.4e-05	9.98e-05	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—LEP—prostate cancer	3.39e-05	0.00178	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.37e-05	0.00177	CbGpPWpGaD
Fosinopril—Diarrhoea—Epirubicin—prostate cancer	3.29e-05	9.65e-05	CcSEcCtD
Fosinopril—Hypersensitivity—Doxorubicin—prostate cancer	3.28e-05	9.62e-05	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—RXRA—prostate cancer	3.21e-05	0.00168	CbGpPWpGaD
Fosinopril—Asthenia—Doxorubicin—prostate cancer	3.19e-05	9.37e-05	CcSEcCtD
Fosinopril—Dizziness—Epirubicin—prostate cancer	3.18e-05	9.33e-05	CcSEcCtD
Fosinopril—Pruritus—Doxorubicin—prostate cancer	3.15e-05	9.23e-05	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—NCOA1—prostate cancer	3.13e-05	0.00164	CbGpPWpGaD
Fosinopril—Vomiting—Epirubicin—prostate cancer	3.06e-05	8.97e-05	CcSEcCtD
Fosinopril—Diarrhoea—Doxorubicin—prostate cancer	3.04e-05	8.93e-05	CcSEcCtD
Fosinopril—Rash—Epirubicin—prostate cancer	3.03e-05	8.89e-05	CcSEcCtD
Fosinopril—Dermatitis—Epirubicin—prostate cancer	3.03e-05	8.89e-05	CcSEcCtD
Fosinopril—Headache—Epirubicin—prostate cancer	3.01e-05	8.84e-05	CcSEcCtD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—RXRA—prostate cancer	2.98e-05	0.00156	CbGpPWpGaD
Fosinopril—Dizziness—Doxorubicin—prostate cancer	2.94e-05	8.63e-05	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—INS—prostate cancer	2.89e-05	0.00152	CbGpPWpGaD
Fosinopril—Nausea—Epirubicin—prostate cancer	2.85e-05	8.38e-05	CcSEcCtD
Fosinopril—Vomiting—Doxorubicin—prostate cancer	2.83e-05	8.3e-05	CcSEcCtD
Fosinopril—Rash—Doxorubicin—prostate cancer	2.8e-05	8.23e-05	CcSEcCtD
Fosinopril—Dermatitis—Doxorubicin—prostate cancer	2.8e-05	8.22e-05	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—IGF1—prostate cancer	2.8e-05	0.00147	CbGpPWpGaD
Fosinopril—Headache—Doxorubicin—prostate cancer	2.79e-05	8.18e-05	CcSEcCtD
Fosinopril—ACE—Metabolism of proteins—MMP2—prostate cancer	2.71e-05	0.00142	CbGpPWpGaD
Fosinopril—Nausea—Doxorubicin—prostate cancer	2.64e-05	7.75e-05	CcSEcCtD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—PPARA—prostate cancer	2.45e-05	0.00129	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—PPARA—prostate cancer	2.27e-05	0.00119	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CXCL8—prostate cancer	2.25e-05	0.00118	CbGpPWpGaD
Fosinopril—ACE—Metabolism of proteins—CTNNB1—prostate cancer	2.08e-05	0.00109	CbGpPWpGaD
Fosinopril—SLC15A2—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.95e-05	0.00102	CbGpPWpGaD
Fosinopril—SLC15A1—Transmembrane transport of small molecules—CREBBP—prostate cancer	1.81e-05	0.000947	CbGpPWpGaD
